[4] KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as Single Agent After Surgery Reduced Risk of Death by 28% Versus Pre-Operative Chemotherapy in Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer (NSCLC). Retrieved October 20, 2023 from https://www.merc...
1. 原发性肺癌诊疗规范(2018年版) 2. Garon EB, Hellmann MD, Rizvi NA, et al. Five-Year Overall Survival for PatientsWith Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: ResultsFrom the Phase I KEYNOTE-001 Study. J Clin Oncol, Published online on 2 June,2019. DOI: 10.1...
完成的18项:经典汇聚,探索未来 成功研究多为单药或者联合化疗用于非驱动突变NSCLC,覆盖后线单药,一线单药,一线联合到辅助单药、围术期新辅助联合化疗/辅助单药,涉及Keynote-010、Keynote-024、Keynote-042、Keynote-189/407、Keynote-091/671系列经典研究;失败的为探...
参考资料: [1] European Commission Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adults With Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based Chemotherapy. Retrieved October 16, 2023, from https://www.merck.com/news/european-commis...
15. Goulart BH, Reyes CM, Fedorenko CR, et al. Referraland treatment patterns among patients with stages III and IV non-small-celllung cancer. J Oncol Pract. 2013;9(1):42–50. 32. Warren JL, Butler EN, Stevens J, et al. ...
2. Garon EB, Hellmann MD, Rizvi NA, et al. Five-Year Overall Survival for PatientsWith Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: ResultsFrom the Phase I KEYNOTE-001 Study. J Clin Oncol, Published online on 2 June,2019. DOI: 10.1200/JCO.19.00934. ...
2. Garon EB, Hellmann MD, Rizvi NA, et al. Five-Year Overall Survival for PatientsWith Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: ResultsFrom the Phase I KEYNOTE-001 Study. J Clin Oncol, Published online on 2 June,2019. DOI: 10.1200/JCO.19.00934. ...
FDA approves Merck’s KEYTRUDA® (pembrolizumab) in Combination with Carboplatin and Either Paclitaxel or Nab-Paclitaxel for the First-Line Treatment of Patients with Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) 我们特别建了“患者交流群”,欢迎肿瘤患者/家属扫描下方二维码,加入交流群,大家一...
5.Herbst R S, Baas P, Kim D W, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial[J]. The Lancet, 2016, 387(10027): 1540-1550. ...
[4] Five-Year Survival Data for Merck’s KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell Lung Cancer (NSCLC) from First KEYNOTE Trial at 2019 ASCO Annual Meeting, Retrieved June 1, 2019, from https://www./news-release/oncology/five-year-survival-data-mercks-keytruda-pembrolizumab-adv...